Acrux, KV to partner on menopause treatment

MELBOURNE, Australia Transdermal drug device company Acrux has signed a licensing deal with KV Pharmaceuticals to bring its menopause symptom product to the United States, according to published reports.

KV has agreed to provide Acrux with the Phase III testing data it used for its regulatory dealings with the Food and Drug Administration in exchange for KV gaining access to Acrux’s drug delivery platform for a further six products.

The technology allows for drugs to pass through the skin either by using a simple applicator or a roll-on product similar to a deodorant.

The first major application has been for drugs to treat menopause symptoms, but the company is also using the technology to deliver drugs to treat testosterone deficiency, relieve chronic pain and help people quit smoking, as well as in an animal health product for dogs.